Nanoparticle-miRNA conjugate reduces inflammation, oxidative stress
Founded by a fetal surgeon who has studied the mechanisms leading to scar-free healing in the fetus for 20+ years, Ceria Therapeutics is dedicated to applying those insights to improve healing in children and adults. Inflammation and oxidative stress are primary causes of aberrant healing in multiple indications. Ceria’s proprietary nanoparticle-miRNA conjugate, delivered locally through a single administration, is designed to reduce inflammation and oxidative stress. Pre-clinical data in animal models show success in indications including diabetic wounds, acute respiratory distress syndrome, heart failure, and colitis. Ceria’s intellectual property is protected by a strong patent portfolio. Ceria Therapeutics has recently filed its pre-IND package with the FDA, and plans to file its first IND in 2020. Ceria is in the process of building a strong management team to support that effort.